These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 15800937

  • 41. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 42. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, Nakashima M, Kanazawa I, STRONG Study Group.
    Mov Disord; 2007 Oct 15; 22(13):1860-5. PubMed ID: 17618525
    [Abstract] [Full Text] [Related]

  • 43. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun 15; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 44. Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial.
    Ondo WG, Silay YS.
    Mov Disord; 2006 Oct 15; 21(10):1614-7. PubMed ID: 16830315
    [Abstract] [Full Text] [Related]

  • 45. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial.
    Lee EY, Lee EB, Park BJ, Lee CK, Yoo B, Lim MK, Shim SC, Sheen DH, Seo YI, Kim HA, Baek HJ, Song YW.
    Clin Ther; 2006 Dec 15; 28(12):2052-60. PubMed ID: 17296461
    [Abstract] [Full Text] [Related]

  • 46. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.
    Lancet Neurol; 2011 May 15; 10(5):415-23. PubMed ID: 21482191
    [Abstract] [Full Text] [Related]

  • 47. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I, Parkinson Study Group TEMPO, PRESTO Investigators.
    J Neurol Sci; 2006 Oct 25; 248(1-2):78-83. PubMed ID: 16828804
    [Abstract] [Full Text] [Related]

  • 48. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R.
    Clin Neuropharmacol; 2010 Oct 25; 33(1):5-10. PubMed ID: 19855267
    [Abstract] [Full Text] [Related]

  • 49. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study.
    Cookson J, Keck PE, Ketter TA, Macfadden W.
    Int Clin Psychopharmacol; 2007 Mar 25; 22(2):93-100. PubMed ID: 17293709
    [Abstract] [Full Text] [Related]

  • 50. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.
    Am J Geriatr Psychiatry; 2008 Jan 25; 16(1):31-43. PubMed ID: 18165460
    [Abstract] [Full Text] [Related]

  • 51. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM.
    Parkinsonism Relat Disord; 2005 Nov 25; 11(7):449-52. PubMed ID: 16154788
    [Abstract] [Full Text] [Related]

  • 52. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1993 Apr 25; 33(4):350-6. PubMed ID: 8489205
    [Abstract] [Full Text] [Related]

  • 53. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial.
    Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC.
    Am J Psychiatry; 2014 Nov 01; 171(11):1174-82. PubMed ID: 24968985
    [Abstract] [Full Text] [Related]

  • 54. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Nov 01; 18(11):1324-31. PubMed ID: 14639675
    [Abstract] [Full Text] [Related]

  • 55. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials.
    Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, Theeuwes AA, Rembrandt/Vermeer Study Groups.
    Mov Disord; 2011 Jul 01; 26(8):1464-76. PubMed ID: 21542016
    [Abstract] [Full Text] [Related]

  • 56. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
    Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, Williams-Hughes C.
    Am J Geriatr Psychiatry; 2006 Sep 01; 14(9):767-76. PubMed ID: 16905684
    [Abstract] [Full Text] [Related]

  • 57. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
    Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH.
    Mov Disord; 2003 May 01; 18(5):510-4. PubMed ID: 12722164
    [Abstract] [Full Text] [Related]

  • 58. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
    Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, Japanese Istradefylline Study Group.
    Mov Disord; 2010 Jul 30; 25(10):1437-43. PubMed ID: 20629136
    [Abstract] [Full Text] [Related]

  • 59. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.
    Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM.
    J Neurol; 2006 Feb 30; 253(2):171-5. PubMed ID: 16096815
    [Abstract] [Full Text] [Related]

  • 60. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
    Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study Group.
    Neurology; 2007 Apr 24; 68(17):1356-63. PubMed ID: 17452579
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.